ActoGeniX, a development stage biopharmaceutical company, announced that the United States´ Food and Drug Administration (FDA) has approved the Company´s Investigational New Drug (IND) application for AG013, a novel therapeutic product for the treatment of oral mucositis in cancer patients. This IND application approval allows ActoGeniX to initiate a phase 1B clinical trial with AG013, which will now become the second clinical development program in ActoGeniX´s portfolio. Continue reading ...
Sunday, May 17, 2009
Saturday, May 16, 2009
Statistical Press Notice - Direct Access Audiology Referral To Treatment (RTT) Times Data February 2009, England
The "Improving Access to Audiology Services in England", document in March 2007 by stated that: "Improving Access to Audiology Services in England sets out a simple aspiration: for local health systems to transform the experience of the audiology service for all their patients. This requires a radical reduction in waiting... Complete news at...
Synosia Therapeutics Begins Phase I Trial Of A New Generation Treatment For Cognitive Impairment In Alzheimer's Disease And Schizophrenia
Synosia Therapeutics Begins Phase I Trial Of A New Generation Treatment For Cognitive Impairment In Alzheimer's Disease And Schizophrenia
Synosia Therapeutics announced today that it has started a Phase I clinical trial of SYN-120, its new generation 5-HT6 antagonist under development for the treatment of cognitive impairment associated with Alzheimer's and schizophrenia. The study will assess the safety and tolerability of single ascending doses of SYN-120 in healthy volunteers.
Synosia Therapeutics announced today that it has started a Phase I clinical trial of SYN-120, its new generation 5-HT6 antagonist under development for the treatment of cognitive impairment associated with Alzheimer's and schizophrenia. The study will assess the safety and tolerability of single ascending doses of SYN-120 in healthy volunteers.
Subscribe to:
Posts (Atom)
